Kalaris Therapeutics, Inc.
KLRS
$7.08
-$0.32-4.32%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
4/4/2025
-
Tickeron - Stocks
4/4/2025
-
TipRanks Financial Blog
4/4/2025
-
The Fly
4/4/2025
-
Globe Newswire
3/26/2025
-
Tickeron - Stocks
3/26/2025
-
Tickeron - Stocks
3/26/2025
-
Tickeron - Stocks
3/18/2025
-
Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Friday, January 17, 2025
Period Date
Sunday, December 31, 2023
Next Filing
Week of Jan 12 and 16 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
Address
628 Middlefield Road
Palo Alto, CA 94301
Palo Alto, CA 94301
Country
Year Founded
Business Description
Sector
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was...
more
